Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Antiplatelet therapy

What have we learned from the ANTARCTIC trial?

Nature Reviews Cardiology volume 13, pages 639–640 (2016)Cite this article

Subjects

The ANTARCTIC trial does not provide sufficient evidence to refute the utility of platelet function monitoring in patients with high risk of coronary artery disease. Future trials on personalized antiplatelet therapy should try to address the limitations of previous studies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gurbel, P. A., Jeong, Y. H., Navarese, E. P. & Tantry, U. S. Platelet-mediated thrombosis: from bench to bedside. Circ. Res. 118, 1380–1391 (2016).

    Article  CAS  Google Scholar 

  2. Cayla, G. et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomized controlled superiority trial. Lancet http://dx.doi.org/10.1016/S0140-6736(16)31323-X (2016).

  3. Gurbel, P. A. et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J. Am. Coll. Cardiol. 46, 1820–1826 (2005).

    Article  CAS  Google Scholar 

  4. Reny, J. L. et al. Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data. Thromb. Haemost. 115, 844–855 (2016).

    PubMed  Google Scholar 

  5. Bonello, L. et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51, 1404–1411 (2008).

    Article  CAS  Google Scholar 

  6. Campo, G. et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J. Am. Coll. Cardiol. 56, 1447–1455 (2010).

    Article  CAS  Google Scholar 

  7. Price, M. J. et al. Standard- versus high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305, 1097–1105 (2011).

    Article  CAS  Google Scholar 

  8. Collet, J. P. et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 367, 2100–2109 (2012).

    Article  CAS  Google Scholar 

  9. Erlinge, D. et al. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J. Am. Coll. Cardiol. 62, 577–583 (2013).

    Article  CAS  Google Scholar 

  10. Gurbel, P. A. et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 308, 1785–1794 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Paul A. Gurbel and Udaya S. Tantry are at Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, 3300 Gallows Road, Falls Church, Virginia 22042, USA.,

    Paul A. Gurbel & Udaya S. Tantry

Authors
  1. Paul A. Gurbel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Udaya S. Tantry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul A. Gurbel.

Ethics declarations

Competing interests

P.A.G. has received consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo/Lilly, Haemonetics, Janssen Pharmaceuticals, Merck, and New Haven Pharmaceuticals; grants from Coramed Technologies, Duke Clinical Research Institute, Haemonetics, Harvard Clinical Research Institute, MedImmune, Merck, National Institutes of Health, New Haven Pharmaceuticals, and Sinnowa. He also owns a patent for platelet function testing, and stock options in Merck. U.S.T. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gurbel, P., Tantry, U. What have we learned from the ANTARCTIC trial?. Nat Rev Cardiol 13, 639–640 (2016). https://doi.org/10.1038/nrcardio.2016.167

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2016.167

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing